CD19 and B-cell chronic lymphocytic leukemia: Importantly, CD19-ReTARGTPR mediated the robust elimination of primary CD19pos cancer cells derived from five patients with chronic lymphocytic leukemia (CLL) (Figure 2D,E and Figure A1E).